変力薬の世界市場レポート 2025年

変力薬の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR12.3％で45億2,000万米ドルに成長します。予測期間の成長は、心血管疾患負担の増加、ドラッグデリバリーシステムの進歩、個別化医療アプローチ、研究資金の増加、併用療法の需要などに起因しています。予測期間の主な動向には、患者教育と意識向上、心筋症をターゲットとした治療、心不全管理の重点化、併用療法、安全性プロファイルの改善などがあります。

変力薬市場は、心血管疾患（CVD）の有病率の増加に牽引されて急成長を遂げています。心血管疾患は、血管系および心機能の障害を包含します。変力薬は、心臓の収縮力と機能を強化し、心臓ショックに対処し、心拍数を減少させることにより、これらの疾患の治療に重要な役割を果たしています。心臓の収縮を強化するその能力は、血流の改善につながります。注目すべきことに、2022年10月、米国疾病予防管理センターは、2020年の死者数が69万7,000人であり、米国における主要な死因は心臓病であると報告しています。このことは、死亡者の約5人に1人が心臓病によるものであることから、相当な市場需要があることを裏付けています。さらに、米国心臓病学会（American College of Cardiology）は、2025～2060年にかけて脳卒中リスクが33.8％増加し、1,500万症例に達すると予測しており、心血管疾患の有病率上昇により変力薬市場をさらに促進しています。

ヘルスケア支出の増加は、今後の変力薬市場の成長を牽引すると予測されます。ヘルスケア支出とは、特定のヘルスケアシステムや経済圏において、一定期間にヘルスケアサービス、物品、活動に費やされる総額のことです。ヘルスケア支出の増加は、イノベーションを助長する環境の育成、研究開発の支援、診断能力の強化、高度な心臓治療へのアクセス拡大など、変力薬の使用にプラスの影響を与えます。例えば、2024年1月、米国の政府機関である国立衛生研究所（National Institutes of Health）は、2022年の米国の医療費が4.1％増加し、4兆5,000億米ドルに達したと報告しました。これは2021年に観測された3.2%の増加と比較して、より速い成長率です。このように、ヘルスケア支出の増加が変力薬市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の変力薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の変力薬市場：成長率分析
• 世界の変力薬市場の実績：規模と成長、2019～2024年
• 世界の変力薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の変力薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の変力薬市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 陽性変力薬
• 陰性変力薬
• その他
• 世界の変力薬市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 非経口
• その他
• 世界の変力薬市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 心臓発作
• 心不全
• 狭心症
• 不整脈
• その他
• 世界の変力薬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• その他
• 世界の変力薬市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• ホームケア
• 専門センター
• その他
• 世界の変力薬市場：陽性変力薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 変力配糖体
• カテコールアミン
• ホスホジエステラーゼ阻害剤
• 世界の変力薬市場：陰性変力薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• β遮断薬
• カルシウムチャネル遮断薬
• 世界の変力薬市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 混合変力薬
• 実験的変力薬

第7章 地域別・国別分析

• 世界の変力薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の変力薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 変力薬市場：競合情勢
• 変力薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Johnson & Johnson
• Bayer AG
• Merck & Co. Inc.
• Bristol-Myers Squibb Company
• Cipla Ltd.
• Eli Lilly And Company
• Sanofi S.A.
• Baxter International Inc.
• Hikma Pharmaceuticals plc
• Sun Pharmaceuticals Industries Ltd.
• Cadila Pharmaceuticals Ltd.
• AbbVie Inc.
• Allergan plc
• Amgen Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 変力薬市場2029年：新たな機会を提供する国
• 変力薬市場2029年：新たな機会を提供するセグメント
• 変力薬市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Inotropic agents constitute a category of medications that impact the contractility of the heart muscle, serving as a treatment for conditions such as heart failure, where the heart struggles to pump a sufficient amount of blood to meet the body's requirements. These agents function by augmenting the strength and vigor of the heart's contractions, thereby enhancing blood flow to the organs and tissues of the body.

The primary classifications within the realm of inotropic agents encompass positive inotropic drugs, negative inotropic drugs, and others. Positive inotropic drugs are medications designed to amplify the contractility or force of contraction in the heart muscle. Administration methods include oral, parenteral, and other routes, with distribution channels spanning hospital pharmacies, retail pharmacies, and others. Their application extends to treating diverse conditions such as heart attack, heart failure, angina, arrhythmia, among others. The primary end-users comprise hospitals, homecare, specialty centers, and others.

The inotropic agents market research report is one of a series of new reports from The Business Research Company that provides inotropic agents market statistics, including inotropic agents industry global market size, regional shares, competitors with a inotropic agents market share, detailed inotropic agents market segments, market trends and opportunities, and any further data you may need to thrive in the inotropic agents industry. This inotropic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inotropic agents market size has grown rapidly in recent years. It will grow from$2.56 billion in 2024 to $2.84 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to education and awareness initiatives, expansion of cardiac treatment options, development of safer agents, improved patient outcomes, regulatory approvals

The inotropic agents market size is expected to see rapid growth in the next few years. It will grow to $4.52 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to growing cardiovascular disease burden, advancements in drug delivery systems, personalized medicine approach, increasing research funding, demand for combination therapies. Major trends in the forecast period include patient education and awareness, targeting cardiomyopathies, focus on heart failure management, combination therapies, improved safety profiles.

The inotropic agent market is experiencing a surge in growth, driven by the increasing prevalence of cardiovascular diseases (CVDs). Cardiovascular diseases encompass disorders of the vascular system and heart function. Inotropic agents play a crucial role in treating these conditions by enhancing heart contractility and function, addressing cardiac shock, and reducing heart rate. Their ability to strengthen heart contractions leads to improved blood flow. Notably, in October 2022, the Centers for Disease Control and Prevention reported heart diseases as the leading cause of death in the US, with 697,000 deaths in 2020. This underscores the substantial market demand, as approximately 1 in every 5 deaths resulted from heart disease. Moreover, the American College of Cardiology projected a 33.8 percent increase in stroke risk, reaching 15 million cases from 2025 to 2060, further propelling the inotropic agent market due to the escalating prevalence of cardiovascular diseases.

The increasing healthcare expenditure is projected to drive the growth of the inotropic agents market in the future. Healthcare expenditure refers to the total amount spent on healthcare services, goods, and activities within a specific healthcare system or economy over a defined period. Rising healthcare expenditure positively impacts the use of inotropic agents by fostering an environment conducive to innovation, supporting research and development, enhancing diagnostic capabilities, and ensuring greater access to advanced cardiac care. For instance, in January 2024, the National Institutes of Health, a U.S.-based government agency, reported that healthcare expenditure in the U.S. rose by 4.1% in 2022, reaching $4.5 trillion, which is a faster growth rate compared to the 3.2% increase observed in 2021. Thus, the rise in healthcare expenditures is driving the growth of the inotropic agents market.

A key trend in the inotropic agents market is the emphasis on drug approval. Major companies in the market are actively developing innovative products and drugs to maintain their market positions. For example, in April 2022, Bristol-Myers Squibb secured regulatory approval from the U.S. Food and Drug Administration for Camzyos(TM) (mavacamten), a medication designed to treat class II-III obstructive hypertrophic cardiomyopathy (HCM). This drug inhibits excessive heart muscle contraction by selectively targeting cardiac myosin, a protein involved in muscle contraction. The approval of such novel drugs contributes to the overall growth and dynamism of the inotropic agents market.

A notable trend in the market is drug patent approval, which serves as a strategy for major companies to sustain their market standing. In October 2022, Windtree Therapeutics, Inc. obtained a patent for istaroxime, a groundbreaking drug candidate with a unique dual mechanism of action for treating heart failure. Istaroxime represents a first-in-class investigational drug with a distinct dual mechanism of action, signifying a potential breakthrough in cardiovascular medicine and offering hope for improved patient outcomes.

In March 2022, Pfizer Inc., a prominent pharmaceutical and biotechnology corporation, completed the acquisition of Arena Pharmaceuticals Inc. for $6.7 billion. This strategic move by Pfizer aims to enhance cardiovascular treatments and capabilities, aligning with the company's mission to deliver important medicines to patients. Arena Pharmaceuticals, Inc., a biopharmaceutical company specializing in inotropic and cardiovascular drugs, adds significant value to Pfizer's portfolio through this acquisition.

Major companies operating in the inotropic agents market include Pfizer Inc., GSK plc, Novartis AG, Mylan N.V., Boehringer Ingelheim International GmbH, AstraZeneca plc, Johnson & Johnson, Bayer AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Cipla Ltd., Eli Lilly And Company, Sanofi S.A., Baxter International Inc., Hikma Pharmaceuticals plc, Sun Pharmaceuticals Industries Ltd., Cadila Pharmaceuticals Ltd., AbbVie Inc., Allergan plc, Amgen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Fresenius Kabi AG, Genentech Inc., GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., Lupin Limited, Regeneron Pharmaceuticals Inc., Roche Holding AG, BioNTech SE

North America was the largest region in the inotropic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global inotropic agents market report during the forecast period. The regions covered in the inotropic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the inotropic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The inotropic agent market consists of sales of digoxin, dopamine, dobutamine, levosimendan, and milrinone. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inotropic Agents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inotropic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inotropic agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inotropic agents market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Positive Inotropic Drugs; Negative Inotropic Drugs; Other Types
• 2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 3) By Indication: Heart Attack; Heart Failure; Angina; Arrhythmia; Other Indications
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
• 5) By End User: Hospital; Homecare; Specialty Centers; Other End Users
• Subsegments:
• 1) By Positive Inotropic Drugs: Cardiac Glycosides; Catecholamines; Phosphodiesterase Inhibitors
• 2) By Negative Inotropic Drugs: Beta Blockers; Calcium Channel Blockers
• 3) By Other Types: Mixed Inotropic Drugs; Experimental Inotropic Agents
• Companies Mentioned: Pfizer Inc.; GSK plc; Novartis AG; Mylan N.V.; Boehringer Ingelheim International GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Inotropic Agents Market Characteristics

3. Inotropic Agents Market Trends And Strategies

4. Inotropic Agents Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Inotropic Agents Growth Analysis And Strategic Analysis Framework

• 5.1. Global Inotropic Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Inotropic Agents Market Growth Rate Analysis
• 5.4. Global Inotropic Agents Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Inotropic Agents Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Inotropic Agents Total Addressable Market (TAM)

6. Inotropic Agents Market Segmentation

• 6.1. Global Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Positive Inotropic Drugs
• Negative Inotropic Drugs
• Other Types
• 6.2. Global Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.3. Global Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Heart Attack
• Heart Failure
• Angina
• Arrhythmia
• Other Indications
• 6.4. Global Inotropic Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.5. Global Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Homecare
• Specialty Centers
• Other End Users
• 6.6. Global Inotropic Agents Market, Sub-Segmentation Of Positive Inotropic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiac Glycosides
• Catecholamines
• Phosphodiesterase Inhibitors
• 6.7. Global Inotropic Agents Market, Sub-Segmentation Of Negative Inotropic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Beta Blockers
• Calcium Channel Blockers
• 6.8. Global Inotropic Agents Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mixed Inotropic Drugs
• Experimental Inotropic Agents

7. Inotropic Agents Market Regional And Country Analysis

• 7.1. Global Inotropic Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Inotropic Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Inotropic Agents Market

• 8.1. Asia-Pacific Inotropic Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Inotropic Agents Market

• 9.1. China Inotropic Agents Market Overview
• 9.2. China Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Inotropic Agents Market

• 10.1. India Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Inotropic Agents Market

• 11.1. Japan Inotropic Agents Market Overview
• 11.2. Japan Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Inotropic Agents Market

• 12.1. Australia Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Inotropic Agents Market

• 13.1. Indonesia Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Inotropic Agents Market

• 14.1. South Korea Inotropic Agents Market Overview
• 14.2. South Korea Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Inotropic Agents Market

• 15.1. Western Europe Inotropic Agents Market Overview
• 15.2. Western Europe Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Inotropic Agents Market

• 16.1. UK Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Inotropic Agents Market

• 17.1. Germany Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Inotropic Agents Market

• 18.1. France Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Inotropic Agents Market

• 19.1. Italy Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Inotropic Agents Market

• 20.1. Spain Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Inotropic Agents Market

• 21.1. Eastern Europe Inotropic Agents Market Overview
• 21.2. Eastern Europe Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Inotropic Agents Market

• 22.1. Russia Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Inotropic Agents Market

• 23.1. North America Inotropic Agents Market Overview
• 23.2. North America Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Inotropic Agents Market

• 24.1. USA Inotropic Agents Market Overview
• 24.2. USA Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Inotropic Agents Market

• 25.1. Canada Inotropic Agents Market Overview
• 25.2. Canada Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Inotropic Agents Market

• 26.1. South America Inotropic Agents Market Overview
• 26.2. South America Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Inotropic Agents Market

• 27.1. Brazil Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Inotropic Agents Market

• 28.1. Middle East Inotropic Agents Market Overview
• 28.2. Middle East Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Inotropic Agents Market

• 29.1. Africa Inotropic Agents Market Overview
• 29.2. Africa Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Inotropic Agents Market Competitive Landscape And Company Profiles

• 30.1. Inotropic Agents Market Competitive Landscape
• 30.2. Inotropic Agents Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

31. Inotropic Agents Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Johnson & Johnson
• 31.3. Bayer AG
• 31.4. Merck & Co. Inc.
• 31.5. Bristol-Myers Squibb Company
• 31.6. Cipla Ltd.
• 31.7. Eli Lilly And Company
• 31.8. Sanofi S.A.
• 31.9. Baxter International Inc.
• 31.10. Hikma Pharmaceuticals plc
• 31.11. Sun Pharmaceuticals Industries Ltd.
• 31.12. Cadila Pharmaceuticals Ltd.
• 31.13. AbbVie Inc.
• 31.14. Allergan plc
• 31.15. Amgen Inc.

32. Global Inotropic Agents Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Inotropic Agents Market

34. Recent Developments In The Inotropic Agents Market

35. Inotropic Agents Market High Potential Countries, Segments and Strategies

• 35.1 Inotropic Agents Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Inotropic Agents Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Inotropic Agents Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer